Financial Post
🏢 Postmedia
May 21, 2026
· 4 min read
AI Analyzed
○ Unverifiable
View full audit trail →
858 Therapeutics Announces Initial Data from First-in-Human Phase 1/2 Trial of PARG Inhibitor ETX-19477 to be Presented at 2026 ASCO Annual Meeting
Original article ↗ 🔒 Paywalled source — limited preview availableB.I.A.S. ANALYSIS
CENTER
LEFTCENTERRIGHT
Signal breakdown
Heuristic (v1/v3)
0.00 · CENTER
ML v2 (DistilBERT)
0.245 · RIGHT
Ensemble
0.122 · CENTER
🏦 Source Intelligence
Rolling outlet bias
CENTER
avg -0.026
5,041 articles tracked
7-day bias trend
LcenterR
V.E.R.I.F.Y. has fact-checked this article.
Subscribe to see claim-by-claim verdicts and reasoning.
Subscribe to see claim-by-claim verdicts and reasoning.
Article Excerpt
This section is Partnership Content supplied by Business Wire Article content — ETX-19477 demonstrated robust efficacy, with a 57% objective response rate in BRCA-mutated platinum-resistant ovarian cancer and earlier-line HR+/HER2- breast cancer (n=7) — Article content — Favorable safety profile, including low rates of hematologic toxicity, supports further monotherapy development and future combination strategies — Article content Article content — These data provide the first clinical proof-of-concept for PARG inhibition in ovarian and breast cancer, including durable RECIST responses in bot…
Read full article at Financial Post ↗
How we scored this article
WTF uses a two-tier system: every article gets a heuristic bias score from keyword analysis, and priority articles (high overlap across 3+ outlets or strong heuristic signal) get full LLM analysis from B.I.A.S. and V.E.R.I.F.Y.
Analyzed by
B.I.A.S.
V.E.R.I.F.Y.
L.O.C.A.L.
quick v1
Jun 1, 2026